Interestingly, while variants of EZH2 were previously shown to associate with adverse clinical outcome in MDS [17] and were in our study predictive of adverse response to AZA, the variants in CDKN2A were not yet previously considered (see Figure 6, Table 1). The gene discussed is CDKN2A; the disease is myelodysplastic syndrome.